Sign In
Buy WGS
$63.85
-1.79 (-2.73%)
At Close: Jul 13, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
05:00pm, Tuesday, 25'th Feb 2025
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Shareholders to Connect
10:00am, Tuesday, 25'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (
Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols
11:00am, Monday, 24'th Feb 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that the American Journal of Human Genetics published peer-reviewed research from the Seqfirst-neo study.
4 Healthcare Stocks to Buy as the Sector Stages a Comeback
09:15am, Monday, 24'th Feb 2025
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the incoming Trump administration's healthcare policies.
GENEDX HOLDINGS (WGS) Upgraded to Strong Buy: Here's What You Should Know
01:00pm, Friday, 21'st Feb 2025
GENEDX HOLDINGS (WGS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
10:00am, Friday, 21'st Feb 2025
NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ:WGS). Such investors
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
03:00pm, Wednesday, 19'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ:WGS). Such investors are a
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Investors to Connect
10:00am, Wednesday, 19'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (
Reviewing GeneDx Holdings: Exome Testing And EPIC Aura Integration Make It A GARP 'Buy'
09:29am, Wednesday, 19'th Feb 2025
GeneDx excels in comprehensive genome and exome testing using a vast genetic database linking 400+ diseases. The company cuts diagnostic times from years to days, enhancing patient outcomes and reduci
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
06:27pm, Tuesday, 18'th Feb 2025
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to
GeneDx CEO on pediatric genetic testing, future of genome sequencing and share surge
03:54pm, Tuesday, 18'th Feb 2025
Katherine Stueland, GeneDx CEO, joins 'Closing Bell' to discuss company earnings and the future of genome sequencing.
GeneDx Holdings Corp. (WGS) Q4 2024 Earnings Call Transcript
11:02am, Tuesday, 18'th Feb 2025
GeneDx Holdings Corp. (NASDAQ:WGS ) Q4 2024 Results Conference Call February 18, 2025 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - President and Chief Execu
Bronstein, Gewirtz & Grossman, LLC Encourages GeneDx Holdings Corp. (WGS) Stockholders to Inquire about Securities Investigation
10:00am, Tuesday, 18'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (
GeneDx Holdings Corp. (WGS) Q4 Earnings and Revenues Surpass Estimates
08:21am, Tuesday, 18'th Feb 2025
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.59 per share a year ago.
